Menu
Sign In Pricing Add Podcast
Podcast Image

BackTable Urology

Ep. 168 Enhancing Men's Health: The Role of APPs with Kenneth Mitchell, PA-C

Tue, 21 May 2024

Description

In this episode of Backtable Urology Podcast, Ken Mitchell MPAS, PA-C, a certified physician associate, speaks about the role of interprofessional collaboration in treating male sexual dysfunction and infertility. --- CHECK OUT OUR SPONSOR KYZATREX™ https://www.kyzatrex.com --- SYNPOSIS First, Ken highlights his journey into men’s health, sparked by the debut of erectile dysfunction medication and his engagement in vascular medicine. He then discusses how he leveraged his clinical background to address prevalent issues such as erectile dysfunction and testosterone management. Ken emphasizes the importance of education, collaboration, and innovative treatment approaches in providing effective patient care. Dr. Silva and Ken also cover the potential of oral testosterone treatments and their growing acceptance among patients due to convenience and cost-effectiveness. Ken shares insights into his role in advancing APP utilization in urology practices and ensuring comprehensive care coverage. Finally, Ken introduces his nonprofit organization, GUYnecology Men’s Health, an initiative aimed at fostering a broader understanding of preventative care among patients and healthcare professionals. --- TIMESTAMPS 00:00 - Introduction 06:28 - Expanding the Role of APPs in Urology 14:47 - Addressing Testosterone Replacement Therapy 21:40 - Exploring Treatment and Insurance Challenges in Urology Practices 27:35 - The Evolution of Oral Testosterone Treatments 35:29 - Incorporating Telehealth and Enhancing Patient Education 36:03 - Introducing Guynecology: A New Approach to Men’s Health 41:44 - Final Thoughts and Advice for Urologists and APPs --- RESOURCES KYZATREX https://www.kyzatrex.com/ GUYnecology Men’s Health Association https://learnguynecology.org/

Audio
Featured in this Episode

No persons identified in this episode.

Transcription
Comments

There are no comments yet.

Please log in to write the first comment.